TPD A Rising Option For Korean Pharma Seeking New Modalities

SK Biopharm Making Aggressive Move

Highlighted by SK Biopharmaceuticals’ recent decision to acquire the US-based ProteoVant Sciences, Korean pharma firms are stepping up deals and collaborations in the hot TPD space, which is expected to continue to attract global investors and big pharma interest.

popular choice
Korean Firms Actively Looking For Opportunities In TPD • Source: Shutterstock

Targeted protein degradation (TPD) is becoming a popular choice for Korean pharma firms looking for new drug modalities and growth engines. They are making diverse moves, largely seeking R&D collaborations, M&A and investment.

Among them, SK Biopharmaceuticals Co., Ltd, an affiliate of SK Group, has made a strong move; it has announced...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia